LAUSANNE, Switzerland and DANVERS, MA, USA - June 7, 2023
Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, and Cell Signaling Technology (CST), a life science discovery technology company and leading provider of antibodies, kits, and services, today announced a partnership to enable the use of CST® antibodies on the Lunaphore COMET™ platform, a scalable hyperplex imaging solution for fully automated spatial biology.
CST is a trusted provider of high-quality, rigorously validated antibodies for immunohistochemistry (IHC) that can detect key proteins in a variety of disease states. This partnership enables the use of over 1,700 IHC-validated antibodies from CST detected by fluorescent secondary antibodies for use on the COMET™, empowering researchers to develop antibody panels quickly and with confidence. With a comprehensive offering of primary rabbit and mouse antibodies, researchers relying on CST antibody products have the tools they need to enable fully automated hyperplex imaging at scale.
“As a scientist-led company, we understand the importance of validating antibodies in each application independently. We do not infer performance in IHC based on western blot, for example," said Katie Crosby, Sr. Director, Antibody Applications & Validation at CST. "That's why our team at CST has rigorously tested every one of our IHC-validated antibodies to ensure their specificity and sensitivity in IHC assays.”
The COMET™ platform is the first universal, end-to-end spatial biology solution that can assess the location and abundance of a high number of proteins on a single tissue section without the need to conjugate primary antibodies. From early discovery to late-stage translational and clinical research projects, COMET™ can interrogate complex cellular mechanisms to identify new biological pathways in disciplines including immuno-oncology, neuroscience, infectious disease research, and more. COMET™'s walk-away automation maximizes reproducibility while full-tissue preservation capabilities enable additional downstream analysis.
“The COMET™ offers unparalleled flexibility in antibody panel design, and when combined with the comprehensive portfolio of primary antibodies from CST, the research community can confidently generate high-resolution hyperplex images in a matter of days," said Déborah Heintze, CMO at Lunaphore. “The CST products tested on COMET™ gave clear results, demonstrating the capability to produce the high-quality images needed to enable the next generation of spatial biology research."
CST produces and validates more than 99% of its primary antibodies in-house, ensuring shipments will arrive on time and without delay, no matter the size of the order or duration of the project.
“The time and commitment we put into validating and manufacturing our antibodies is recognized by the research community–eight of the 12 most-cited antibodies on CiteAb are from CST, and over one-third of CiteAb's Top 100 list are our products," said Roby Polakiewicz, Chief Scientific Officer at CST. “This partnership provides scientists with that same high level of confidence in antibody sensitivity, specificity, and availability when using Lunaphore's leading spatial biology platform.”
Lunaphore and CST will present data about the antibody validation project at the European Association for Cancer Research (EACR) 2023 Congress to be held 12-15 June 2023 in Torino, Italy. Visit the poster at the upcoming show to learn more:
Studying the immune status of the tumor microenvironment with automated hyperplex immunofluorescence
Poster #: EACR23-0431
Date and time: Wednesday, June 14, 10:15 am - 6:15 pm CEST
COMET™ is the only fully automated, high-throughput, hyperplex platform ensuring scalability and reproducibility without the need to conjugate primary antibodies. COMET™ provides walk-away automation, integrating staining, imaging, and image preprocessing steps to obtain standard hyperplex images. COMET™ generates highly robust and reproducible data with full tissue preservation, allowing researchers to perform downstream modalities such as H&E or transcriptomics using the same slide. Its superior tissue profiling capabilities facilitate the analysis of 40 different spatial markers in each automated run on a tissue slide. In contrast to other spatial biology solutions, COMET™ works with off-the-shelf, label-free primary antibodies, making panel design much more flexible and faster than any other hyperplex solution. COMET™ works with regular glass slides from standard histology workflows; it is validated for human and mouse samples and is compatible with any other animal sample. The platform can be used for a wide range of research applications, allowing for a dramatic improvement in the understanding of disease pathology. Orders of the new COMET™ version can be placed and will be available for shipment in the upcoming months. To learn more about the COMET™ platform, please visit: https://lunaphore.com/products/comet/.
Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore provides solutions based on a game-changing chip technology that can extract spatial proteomic and transcriptomic data from tumors and other tissues, transforming any assay into multiplex spatial biology through a streamlined and easily integrated process. Lunaphore empowers researchers in immunology, immuno-oncology, and neuroscience to push the boundaries of scientific discovery and drug development. Lunaphore's technology enables the identification of biomarker “signatures" with clinical relevance to support the development of diagnostic tools and streamline clinical trials, to ultimately improve patient outcomes. For further information on Lunaphore and its products, please visit https://lunaphore.com.
Cell Signaling Technology (CST) is a different kind of life science company—one founded, owned, and run by active research scientists, with the highest standards of product and service quality, technological innovation, and scientific rigor. Founded in 1999 and headquartered in Danvers, Massachusetts, USA, CST employs over 600 people worldwide. We consistently provide fellow scientists around the globe with best-in-class products and services to fuel their quests for discovery. CST is a company of caring people driven by a devotion to facilitating good science—a company committed to doing the right thing for our Customers, our communities, and our planet. cellsignal.com
CST Media and Press
Rebecca J. Reppucci, MBA
Cell Signaling Technology, Inc.
Senior Director, Global MarComm & Technology
email: [email protected]
Lunaphore Media and Press
Lunaphore Corporate Communications
email: [email protected]